Status:
COMPLETED
Treatment of Patients With Inflammatory-dystrophic Diseases of the Cornea Using Autologous Stem Cells
Lead Sponsor:
Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
Collaborating Sponsors:
Belarusian State Medical University
Conditions:
Corneal Ulcer
Corneal Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
Treatment of patients with inflammatory-dystrophic diseases of the cornea using autologous limbal stem cells (corneal epithelial stem cells) or adipose-derived mesenchymal stem cells
Detailed Description
In order to treat inflammatory and dystrophic diseases of the cornea perilimbal injections of cultured autologous stem cells are performed. Corneal (limbal) epithelial stem cells (LSC) or mesenchymal ...
Eligibility Criteria
Inclusion
- inflammatory-dystrophic diseases of the cornea:
- Epithelial defects of the cornea, ulcerative keratitis of various etiology, resistant to standard methods of treatment
- Dystrophic diseases of the cornea, accompanied by edema
- Burns of the cornea
- Neurotrophic forms of keratitis
- Persistent post-traumatic, postoperative, contusion keratitis and keratopathy
Exclusion
- Pregnancy.
- Viral hepatitis B and C, HIV, tubeculosis and other chronic viral and bacterial infections.
- Cancer or leukemia
- Any diseases in the stage of decompensation.
- Mental disorders.
- Anomalies of eye refraction
Key Trial Info
Start Date :
October 3 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 30 2019
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT04484402
Start Date
October 3 2016
End Date
December 30 2019
Last Update
July 30 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
Minsk, Belarus, 220072